GRI-0621, an experimental oral therapy from GRI Bio, boosts lung function in adults with IPF, according to top-line clinical ...

Columnist Sam Kirton has wonderful memories of holiday presents, but the greatest gift he's received came in the form of a lung transplant.

Caring for someone you love is intimate, humbling, and grounding, writes columnist Ann Reynoso, who swapped caregiver roles with her husband.

Building on positive Phase 2 data, Puretech plans to launch a Phase 3 trial to further evaluate its experimental IPF therapy ...

In her columns debut, Kylene Henderson shares how her family learned to work together after her husband's pulmonary fibrosis diagnosis.

Remembering loved ones who have passed invites waves of grief, but for columnist Sam Kirton, there is also joy to be found in the memories.

A Phase 3 clinical trial testing Boehringer Ingelheim’s oral investigational treatment nerandomilast in people with idiopathic pulmonary fibrosis (IPF) has met its primary goal of demonstrating the ...

The U.S. Food and Drug Administration (FDA) recently granted orphan drug designation to Calluna Pharma‘s CAL101 as a potential treatment for idiopathic pulmonary fibrosis (IPF). This designation is ...

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy for progressive pulmonary fibrosis (PF).

Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The ...

Taking oral dietary supplements of epigallocatechin-3-gallate (EGCG) — an antioxidant in green tea — may stop and reverse the pro-fibrotic (scarring) state of the lungs of people with idiopathic ...